Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Idecabtagene vicleucel has FDA approval in the US. It is also authorized in the EU through the EMA. It is for adults with relapsed or refractory multiple myeloma. This is after two or more prior treatments. These include an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. It is not approved for plasmacytoma as a separate condition (1, 3, 4).
Idecabtagene vicleucel becomes a practice-changing treatment option. This first-in-class therapeutic offers hope for more durable remissions, as well as better quality of life, following a single infusion in …